3869.Hk
3869.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
Business. 3869.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
3869.HK operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare-related products and services.
The company maintains a liquidity position with a current ratio of 1.62, indicating a moderate ability to meet short-term obligations. However, the debt-to-equity ratio of 2.1 suggests a relatively high level of leverage, which could pose a risk to financial stability. The return on equity of 27.15% is strong, reflecting efficient use of shareholders' equity to generate profits. The return on assets of 5.29% is lower than the industry median, indicating that the company may not be utilizing its assets as effectively as its peers.
Profitability metrics show that the company has a gross profit of 267.62 million CNY and an operating income of 121.27 million CNY, translating to a gross margin of 18.2% and an operating margin of 8.24%. These figures are below the industry median for gross margin and operating margin, suggesting that the company may be facing cost pressures or pricing challenges. The net income of 136.42 million CNY represents a net margin of 9.27%, which is also below the industry median, indicating that the company's profitability is not as robust as its peers.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification could expose the company to regional economic downturns or regulatory changes that could impact its revenue streams. The company's revenue history shows a stable performance, with no significant growth or decline in the most recent period.
Looking ahead, the company is expected to maintain its current revenue trajectory, with no significant growth or decline anticipated in the next fiscal year. The risk assessment indicates a medium liquidity risk, primarily due to the company's high debt levels and the fact that net cash is negative after subtracting total debt. The dilution risk is low, as there is no indication of significant share issuance or dilution in the near term.
Recent events, including filings and transcripts, have not revealed any material changes in the company's operations or financial position. The company continues to operate within its established business model, with no significant new initiatives or strategic shifts disclosed.
- The company has a strong return on equity but a lower return on assets compared to the industry median.
- The company's liquidity position is moderate, with a current ratio of 1.62.
- The company's profitability metrics are below the industry median, indicating potential cost or pricing challenges.
- The company's revenue is concentrated in a single segment, which could increase its exposure to regional risks.
- The company is expected to maintain a stable revenue trajectory in the next fiscal year.
- The company has a low dilution risk, with no significant share issuance expected in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- 3869.HK Market data — financials · 2026-05-26